The findings may offer a direction for study of personalized therapy in this select group of triple negative breast cancer patients, as well as highlight the unique need for genetic testing in a patient population.
Ana M. Gonzalez-Angulo, M.D., associate professor in MD Anderson's Departments of Breast Medical Oncology and Systems Biology presented the findings in advance of the 2010 Breast Cancer Symposium.
"There is data on the number of breast cancer patients with BRCA mutations, as well as those that have triple negative disease. However, there is no understanding of the incidence of BRCA1 and 2 mutations in unselected patients with triple negative breast cancer," said Gonzalez-Angulo, the study's first and corresponding author. "Now, there are new drugs that appear to be more effective in treating triple negative breast cancer and BRCA status may be an important way of selecting patients that may respond to these therapies."
Triple negative disease - breast cancer that is estrogen, progesterone and HER2-neu receptor negative - accounts for about 15 percent of all breast cancers. Currently, it's an area of much research focus in the breast cancer community because: it lacks effective targets effective for anti-cancer therapies; chemotherapy is only effective in about 40 percent of patients; and in those that do relapse, the disease is highly resistant and patients die quickly.
PARP inhibitors, a class of drugs of growing interest in cancer research, have shown promise in both patients with BRCA and triple negative disease. PARPs appear to be more effective in patients with BRCA mutations, as both PARP enzymes and proteins produced by the BRCA genes are involved in the repair of DNA. Therefore, the MD Anderson finding may provide an early idea of how to select those triple negative breast cancer patients that may respond best to therapy.
For this study, part of Gonzalez-Angulo's ongoing laboratory project, Molecular Characterization of Triple Negative Breast Cancer, the researchers sent both tumor and normal tissue of 77 women with triple negative disease to Myriad Genetics Inc. to identify germline (inherited) and somatic (in tumor only) BRCA mutations. Of those 77 patients, 15 (19.5 percent), were found to have mutations (14 germline, one somatic) -12 (15.6 percent) with BRCA1 and three (3.9 percent) with BRCA2.
The triple negative breast cancer patients were treated at MD Anderson between 1987 and 2006, and all but one received the same adjuvant chemotherapy regimen. The median follow-up was 43 months. The five-year relapse-free and five-year overall survival of the patients with either BRCA mutation, was 86,2 percent, and 73.3 percent, respectively, compared to 51.7 percent and 52.8 percent, respectively, in patients lacking mutations.
The researchers were surprised by the findings, however, Gonzalez-Angulo notes that prior studies conducted were case-controlled looking at BRCA mutations carriers with all types of breast cancer. The MD Anderson study is the first to look exclusively at women with triple negative breast cancer, an unselected population.
Also surprising, the incidence of BRCA mutations in the triple negative breast cancer population was higher than expected, said Gonazlez-Angulo.
"It was interesting to find that a good portion of these women were not sent to genetic counseling - some didn't meet the criteria to be sent for testing, however they still had BRCA mutations," said Gonazlez-Angulo. "Perhaps we need to lower our threshold for patients with triple negative breast cancer for genetic counseling and to assess for mutation status - especially those under age 50 - despite not having the significant family history as others."
As a follow up, Gonzalez-Angulo plans to continue her ongoing laboratory research, with signaling pathways, RNA, DNA, and other mutations of the disease.
In addition to Gonzalez-Angulo, other authors on the study include, from MD Anderson: Gabriel Hortobagyi, M.D., professor and chair of the Department of Breast Medical Oncology; Banu Arun, M.D., professor in the Departments of Breast Medical Oncology and Clinical Cancer Genetics; Jennifer Litton, M.D., assistant professor, Department of Breast Medical Oncology; Huiqin Chen, Department of Breast Medical Oncology; Funda Meric Bernstam, M.D., professor in the Department of Surgical Oncology; Kim-Anh Do, Ph.D, Department of Biostatistics. From Myriad Genetics Inc., authors include; Jerry S. Lanchbury, Ph.D; Jennifer Potter, Ph.D., Kirsten Timms, Ph.D.
Gonalez-Anuglo has ongoing research collaboration with, but receives no funding from, Myriad Genetics, Inc.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For seven of the past nine years, including 2010, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.
Laura Sussman | EurekAlert!
Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University
New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg
A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.
In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...
A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.
By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
23.02.2018 | Physics and Astronomy
23.02.2018 | Health and Medicine
23.02.2018 | Physics and Astronomy